Extended Data Fig. 10: Mutation analysis and response.
From: The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
This cohort included 37 patients evaluable for this analysis. CR, complete remission; CRh, complete remission with partial haematologic recovery; CRp, complete remission with incomplete platelet recovery; MLFS, morphologic leukaemia-free state; NR, not reached; PD, progressive dVAF, variant allele frequency.
